XNASZYXI
Market cap257mUSD
Jan 07, Last price
8.10USD
1D
0.25%
1Q
5.06%
Name
Zynex Inc
Chart & Performance
Profile
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 184,322 16.54% | 158,167 21.39% | |||||||
Cost of revenue | 182,742 | 142,329 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 1,580 | 15,838 | |||||||
NOPBT Margin | 0.86% | 10.01% | |||||||
Operating Taxes | 2,847 | 5,150 | |||||||
Tax Rate | 180.19% | 32.52% | |||||||
NOPAT | (1,267) | 10,688 | |||||||
Net income | 9,732 -42.91% | 17,048 -0.32% | |||||||
Dividends | (3) | (3,613) | |||||||
Dividend yield | 0.00% | 0.66% | |||||||
Proceeds from repurchase of equity | (37,838) | (26,380) | |||||||
BB yield | 9.61% | 4.85% | |||||||
Debt | |||||||||
Debt current | 7,850 | 7,937 | |||||||
Long-term debt | 90,806 | 35,355 | |||||||
Deferred revenue | (3,884) | ||||||||
Other long-term liabilities | 10,000 | ||||||||
Net debt | 54,077 | 23,148 | |||||||
Cash flow | |||||||||
Cash from operating activities | 17,756 | 13,746 | |||||||
CAPEX | (1,206) | (418) | |||||||
Cash from investing activities | (966) | (418) | |||||||
Cash from financing activities | 7,645 | (35,796) | |||||||
FCF | 572 | 3,446 | |||||||
Balance | |||||||||
Cash | 44,579 | 20,144 | |||||||
Long term investments | |||||||||
Excess cash | 35,363 | 12,236 | |||||||
Stockholders' equity | 26,813 | 17,087 | |||||||
Invested Capital | 99,409 | 85,202 | |||||||
ROIC | 10.86% | ||||||||
ROCE | 1.25% | 15.63% | |||||||
EV | |||||||||
Common stock shares outstanding | 36,142 | 39,127 | |||||||
Price | 10.89 -21.71% | 13.91 39.52% | |||||||
Market cap | 393,586 -27.68% | 544,257 26.61% | |||||||
EV | 447,663 | 567,405 | |||||||
EBITDA | 5,800 | 18,965 | |||||||
EV/EBITDA | 77.18 | 29.92 | |||||||
Interest | 1,094 | 440 | |||||||
Interest/NOPBT | 69.24% | 2.78% |